Calidar

Calidar is a private, pre-revenue biotech company developing a novel diagnostic imaging platform called 4D Mammography. The technology utilizes X-ray diffraction to capture molecular-level signatures or 'tissue fingerprints' associated with cancer, aiming to improve the precision of breast cancer screening and diagnosis without the need for biopsy or contrast agents. The company achieved a first-in-human milestone in August 2025, initiating a pilot study for its lead program. Calidar's value proposition centers on providing a fast, lower-dose, and noninvasive tool that could potentially reduce false positives and enable earlier intervention in breast cancer care.

Next-generation X-ray diffraction imaging that measures molecular-level scatter signatures ('tissue fingerprints') to detect disease noninvasively.

Calidar competes in the advanced breast imaging space against established modalities like 3D tomosynthesis, contrast-enhanced mammography, breast MRI, and emerging technologies like molecular breast imaging (MBI) and AI-assisted diagnostics. Its key differentiator is the direct measurement of molecular signatures via X-ray diffraction, a fundamentally different approach than anatomical or metabolic imaging.